Kythera Biopharmaceuticals Inc Sample Contracts

UNDERWRITING AGREEMENT KYTHERA Biopharmaceuticals, Inc. 2,604,168 Shares of Common Stock Underwriting Agreement
Underwriting Agreement • March 16th, 2015 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • New York

KYTHERA Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 2,604,168 shares of common stock, par value $0.00001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 390,625 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.

AutoNDA by SimpleDocs
KYTHERA BIOPHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT
Indemnification Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware

This Indemnification Agreement (“Agreement”) is effective as of [·] by and between Kythera Biopharmaceutical, Inc., a Delaware corporation (the “Company”), and «Indemnitee» (“Indemnitee”).

Contract
Kythera Biopharmaceuticals Inc • May 17th, 2012 • Pharmaceutical preparations • California

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS IS AVAILABLE WITH RESPECT THERETO.

KYTHERA BIOPHARMACEUTICALS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT
Stock Option Agreement • September 2nd, 2014 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware

Kythera Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2014 Employment Commencement Incentive Plan (the “Plan”), hereby grants to the individual listed below (the “Optionee”), an option to purchase the number of shares of the common stock of the Company (“Shares”), set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein and in the Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.

KYTHERA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT
Employment Agreement • March 26th, 2013 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • California

This Employment Agreement (the “Agreement”) is entered into as of March 23, 2013 (the “Effective Date”) by and between Kythera Biopharmaceuticals, Inc. (the “Company”) and Frederick Beddingfield, III, MD, PhD (“Employee”).

Kythera Biopharmaceuticals, Inc.
2004 Stock Plan • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • California

Unless otherwise defined herein, the terms defined in the 2004 Stock Plan shall have the same defined meanings in this Stock Option Agreement.

AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among ALLERGAN PLC, KETO MERGER SUB, INC. and KYTHERA BIOPHARMACEUTICALS, INC. dated as of August 4, 2015
Agreement and Plan of Merger • August 5th, 2015 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware

This AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER (as amended, modified or supplemented from time to time in accordance with its terms, this "Agreement" or this "Amended and Restated Agreement"), dated as of August 4, 2015 (the "Execution Date"), is by and among Allergan plc, a company incorporated under the laws of Ireland (formerly known as Actavis plc) ("Parent"), Keto Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), and KYTHERA Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and amends and restates in its entirety that certain Agreement and Plan of Merger, dated as of June 17, 2015 (the "Original Execution Date"), by and among Parent, Merger Sub and the Company (the "Original Merger Agreement"), as amended by Amendment No. 1 by and among Parent, Merger Sub and the Company, dated as of July 1, 2015 ("Amendment No. 1"). All capitalized terms used in this Agreement shall have the meanings ascribed to such

First Amendment to Manufacturing and Supply Agreement
And Supply Agreement • June 11th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations

This First Amendment to the Manufacturing and Supply Agreement (this “Amendment”) is made as of the 21 of May, 2012 (the “Effective Date of this Amendment”) by and between Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware, with offices at 235 E. 42nd Street, New York, NY 10017 (“Pfizer”) and Kythera Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having an address of 27200 Agoura Road, Calabasas, California 91301 (hereinafter “Customer”).

SECOND AMENDMENT TO LICENSE AGREEMENT
License Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations

This SECOND AMENDMENT TO LICENSE AGREEMENT (“Second Amendment”) is entered into as of April 2, 2012 (“Second Amendment Effective Date”) by and between BAYER CONSUMER CARE AG, a company organized under the laws of the Switzerland (“BCC”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Kythera”).

SECOND AMENDMENT TO OFFICE LEASE
Office Lease • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • California

THIS SECOND AMENDMENT TO OFFICE LEASE (this “Amendment”) is entered into as of the 21 day of April, 2011 by and between 27200 Associates, LLC, a California limited liability company (“Lessor”), and Kythera Biopharmaceuticals, Inc., a Delaware corporation (“Lessee”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • March 10th, 2014 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of March 7, 2014, by and between KYTHERA Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), KYTHERA Holdings Ltd., a company incorporated under the laws of Bermuda (“KHL”) and Bayer Consumer Care AG, a company organized under the laws of Switzerland (“Bayer”).

MANUFACTURING AND SUPPLY AGREEMENT
Manufacturing and Supply Agreement • June 11th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • New York

THIS MANUFACTURING AND SUPPLY AGREEMENT dated as of July 7, 2009 (the “Effective Date”) is made by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware, having an address of 235 East 42nd Street, New York, New York 10017 (hereinafter “Pfizer” or “Company”) and Kythera Biopharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having an address of 27200 Agoura Road, Calabasas, California 91301 (hereinafter “Customer” or “Purchaser”). Purchaser and Company may be referred to herein individually as a “Party” or collectively as the “Parties.”

COMMERCIAL DEVELOPMENT AND SUPPLY AGREEMENT BY AND BETWEEN KYTHERA BIOPHARMACEUTICALS, INC. AND CAMBRIDGE MAJOR LABORATORIES, INC.
Commercial Development and Supply Agreement • May 13th, 2013 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware

This COMMERCIAL DEVELOPMENT AND SUPPLY AGREEMENT (this “Agreement”) is entered into as of April 1, 2013, (the “Effective Date”) by and between Kythera Biopharmaceuticals, Inc., having its principal place of business at 27200 West Agoura Road, Suite 200, Calabasas, CA 91301 (“Purchaser”) and Cambridge Major Labs, Inc. with its principal place of business located at W132 N1055 Grant Drive, Germantown, WI 53022 (“Supplier”). Purchaser and Supplier may be referred to herein each, individually, as a “Party” or, collectively, as the “Parties”. Capitalized terms shall have the meanings set forth in this Agreement.

RESTRUCTURING AGREEMENT BETWEEN BAYER CONSUMER CARE AG AND KYTHERA BIOPHARMACEUTICALS, INC.
Restructuring Agreement • May 8th, 2014 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • New York

THIS RESTRUCTURING AGREEMENT (this “Restructuring Agreement”), is entered into as of March 7, 2014 (the “Effective Date”), by and among Bayer Consumer Care AG, a company organized under the laws of Switzerland (“Bayer”) and KYTHERA Biopharmaceuticals, Inc., a Delaware corporation (“Kythera”) (each, a “Party” and together, the “Parties”) and, with respect to Article 3 and Article 6 hereof only, Intendis GmbH, a company organized under the laws of the Federal Republic of Germany (“Intendis”).

ASSIGNMENT AND NOVATION AGREEMENT BETWEEN BAYER CONSUMER CARE AG AND KYTHERA HOLDINGS LTD.
Assignment and Novation Agreement • May 8th, 2014 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • New York

THIS ASSIGNMENT AND NOVATION AGREEMENT (this “Agreement”), is entered into as of March 7, 2014 (the “Effective Date”), by and among Bayer Consumer Care AG, a company organized under the laws of Switzerland (“Bayer”) and KYTHERA Holdings Ltd., a company incorporated under the laws of Bermuda (“KHL”) (each, a “Party” and together, the “Parties”) and, with respect to Article 2 and Sections 5.3 and 8.4 hereof only, KYTHERA Biopharmaceuticals Inc., a Delaware corporation (“Parent”).

FIFTH AMENDMENT TO OFICE LEASE
Ofice Lease • March 17th, 2014 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • California

THIS FIFTH AMENDMENT TO OFFICE LEASE (this “Amendment”) is entered into as of the 29 day of January 2014 by and between 27200 Associates, LLC, a California limited liability company (“Lessor’), and Kythera Biopharmaceuticals, Inc., a Delaware corporation, (“Lessee’).

KYTHERA BIOPHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT August 30, 2011
Investor Rights Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • California

This Third Amended and Restated Investor Rights Agreement (this “Agreement”) is made as of August 30, 2011, by and among Kythera Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons and entities (each, an “Investor” and collectively, the “Investors”) listed on Exhibit A hereto. Unless otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section 1.

SECOND AMENDMENT TO SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT
Development and Collaboration Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations

This SECOND AMENDMENT TO SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT (“Second Amendment”) is entered into as of April 2, 2012 (“Second Amendment Effective Date”) by and between INTENDIS GMBH., a company organized under the laws of the Federal Republic of Germany (“Intendis”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Kythera”).

FIRST AMENDMENT TO LICENSE AGREEMENT
License Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations

This FIRST AMENDMENT TO LICENSE AGREEMENT (“First Amendment”) is entered into as of March 21, 2011 (“First Amendment Effective Date”) by and between BAYER CONSUMER CARE AG, a company organized under the laws of the Switzerland (“BCC”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Kythera”).

AESTHERX, INC. WARRANT TO PURCHASE SHARES
Kythera Biopharmaceuticals Inc • May 17th, 2012 • Pharmaceutical preparations • California

This Warrant is issued to or its registered assign (the “Holder”) by AESTHERX, INC., a Delaware corporation (the “Company”), pursuant to the terms of that certain Note and Warrant Purchase Agreement (the “Note Purchase Agreement”) of even date herewith, in connection with the Company’s issuance to the holder of this Warrant of a Convertible Promissory Note (the “Note”). This Warrant is one of the “Series B Warrants” issued pursuant to the Note and Purchase Agreement. Pursuant to the terms of the Note Purchase Agreement, simultaneously with a Replacement Event (as defined in the Note Purchase Agreement), (i) without any further action of the Company or the Holder, this Warrant shall be automatically cancelled and neither the Company nor the Holder shall have any rights arising hereunder and (ii) the Company shall issue to each Holder as a replacement for this Warrant a Fallback Warrant (as defined in the Note Purchase Agreement).

THIRD AMENDMENT TO OFFICE LEASE
Office Lease • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • California

THIS THIRD AMENDMENT TO OFFICE LEASE (this “Amendment”) is entered into as of the 23 day of March, 2012 by and between 27200 Associates, LLC, a California limited liability company (“Lessor”), and Kythera Biopharmaceuticals, Inc., a Delaware corporation (“Lessee”).

AutoNDA by SimpleDocs
NOTE
Kythera Biopharmaceuticals Inc • March 10th, 2014 • Pharmaceutical preparations

FOR VALUE RECEIVED, KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), located at 27200 West Agoura Road, Suite 200, Calabasas, CA 91301, promises to pay to the order of KYTHERA HOLDINGS LTD., a wholly-owned subsidiary of Borrower and a company incorporated under the laws of Bermuda (“Lender”), the principal amount of Fifty One Million and No/100 Dollars ($51,000,000.00) (as such amount may be increased or decreased from time to time pursuant to the terms hereof, the “Principal Amount”), together with interest on the Principal Amount for the period commencing on the date hereof until all amounts due hereunder are paid in full in cash, at the rates per annum and on the dates provided below.

AMENDMENT TO LICENSE AGREEMENT
License Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations

This Amendment to License Agreement (this “Amendment”), effective as of August 18, 2010 (the “Amendment Effective Date”) by and between Kythera Biopharmaceuticals, Inc., a Delaware corporation located at 27200 West Agoura Rd., Ste. 200, Calabasas, CA 91301 (“Kythera”) and Los Angeles Biomedical Research Institute at Harbor/UCLA Medical Center, a not-for-profit corporation organized under the laws of California with a principal place of business at 1124 West Carson Street, Torrance, CA 90502 (“LA BioMed”).

LICENSE AGREEMENT DATED AS OF FEBRUARY , 2015 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND KYTHERA HOLDINGS, LTD. AND KYTHERA BIOPHARMACEUTICALS, INC.
License Agreement • March 2nd, 2015 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • Pennsylvania

This License Agreement (this “Agreement”) is dated as of February , 2015 (the “Effective Date”) by and among The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), Kythera Holdings, Ltd., a Bermuda company (“Licensee”), and Kythera Biopharmaceuticals, Inc., a Delaware Corporation (“KBI”). Penn, Licensee and KBI (for purposes of Section 6.4.1) may be referred to herein as a “Party” or, collectively, as “Parties”.

Second Amendment to Manufacturing and Supply Agreement
And Supply Agreement • March 2nd, 2015 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations

This Second Amendment to the Manufacturing and Supply Agreement (this “Second Amendment”) is made as of October 17, 2014 (the “Effective Date of this Second Amendment”) by and between Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware, with offices at 235 E. 42nd Street, New York, NY 10017 (“Pfizer”) and Kythera Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having an address of 30930 Russell Ranch Road, Third Floor, Westlake Village, CA 91362 (hereinafter “Customer”).

LICENSE AGREEMENT
License Agreement • March 2nd, 2015 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations

This license agreement (the “Agreement”) is effective as of February __, 2015 (the “Effective Date”) by and among ACTELION PHARMACEUTICALS, LTD., a Swiss company located at Gewerbestrasse 16, CH-4123 Allschwil, Switzerland (“Actelion”), KYTHERA HOLDINGS, LTD., a Bermuda company located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (“Kythera”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware company located at 30930 Russell Ranch Road, 3rd Floor, Westlake Village, CA 91362, United States of America (“KBI”). Actelion, Kythera and KBI (but only with respect to section 12.5) are referred to individually as a “Party” and collectively as the “Parties”.

TERMINATION AND WAIVER AGREEMENT
Termination and Waiver Agreement • November 5th, 2014 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • New York

This Termination and Waiver Agreement (this “Agreement”) is dated as of November 5, 2014, by and among KYTHERA Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), KYTHERA Holdings Ltd., a company incorporated under the laws of Bermuda (“KHL”) (solely for purposes of Article II hereof), and Bayer Consumer Care AG, a company organized under the laws of Switzerland (“Bayer”).

FOURTH AMENDMENT TO OFFICE LEASE
Office Lease • May 13th, 2013 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • California

THIS FOURTH AMENDMENT TO OFFICE LEASE (this “Amendment”) is entered into as of the 28th day of March 2013 by and between 27200 Associates, LLC, a California limited liability company (“Lessor”), and Kythera Biopharmaceuticals, Inc., a Delaware corporation (“Lessee”).

SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT
Development and Collaboration Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • New York

THIS SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT (this “Collaboration Agreement”) is entered into as of August 26, 2010 (the “Effective Date”) by and between INTENDIS GMBH., a company organized under the laws of the Federal Republic of Germany (“Intendis”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Kythera”). Kythera and Intendis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

AMENDMENT NO. 03 Dated November 30, 2012 TO that certain Loan and Security Agreement No. 1991 dated as of March 21, 2011, as amended (“Agreement”), by and between LIGHTHOUSE CAPITAL PARTNERS VI, L.P. (“Lender”) and KYTHERA BIOPHARMACEUTICALS, INC....
Kythera Biopharmaceuticals Inc • December 5th, 2012 • Pharmaceutical preparations

WHEREAS, Borrower has requested that Lender modify certain terms of its existing term loan financing under the Agreement;

LOAN AND SECURITY AGREEMENT NO. 1991
Secured Promissory Note • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • California

THIS LOAN AND SECURITY AGREEMENT NO. 1991 (this “Agreement”) is entered into as of March 21, 2011, by and between LIGHTHOUSE CAPITAL PARTNERS VI, L.P. (“Lender”) and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Borrower”) and sets forth the terms and conditions upon which Lender will lend and Borrower will repay money. In consideration of the mutual covenants herein contained, the parties agree as follows:

SENIOR ADVISOR TO THE BOARD OF DIRECTORS AGREEMENT
Board of Directors Agreement • April 2nd, 2013 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • California

This Sr. Advisor to the Board of Directors Agreement (“Agreement”) is entered into as of March 28, 2013 (the “Effective Date”) by and between KYTHERA Biopharmaceuticals, Inc. (the “Company”) and Patricia Walker, MD, PhD (“Sr. Advisor”). The Company desires to retain Sr. Advisor as an independent contractor to perform consulting services for the Company, and Sr. Advisor is willing to perform such services, on the terms described below. In consideration of the mutual promises contained herein, the parties agree as follows:

FIRST AMENDMENT TO SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT
Development and Collaboration Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations

This FIRST AMENDMENT TO SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT (“First Amendment”) is entered into as of November 17,2010 (“First Amendment Effective Date”) by and between INTENDIS GMBH., a company organized under the Jaws of the Federal Republic of Germany (“Intendis”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (‘‘Kythera”).

Time is Money Join Law Insider Premium to draft better contracts faster.